CN113784717A - 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 - Google Patents

一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 Download PDF

Info

Publication number
CN113784717A
CN113784717A CN202080033296.0A CN202080033296A CN113784717A CN 113784717 A CN113784717 A CN 113784717A CN 202080033296 A CN202080033296 A CN 202080033296A CN 113784717 A CN113784717 A CN 113784717A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
diazaspiro
trifluoroethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080033296.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿隆索-加力西亚
D·卡朋特
T·帕克
M·罗兹
J·鲁尔卡
S·灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altawante Science
Original Assignee
Altawante Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altawante Science filed Critical Altawante Science
Publication of CN113784717A publication Critical patent/CN113784717A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080033296.0A 2019-03-15 2020-03-13 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 Pending CN113784717A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819162P 2019-03-15 2019-03-15
US62/819,162 2019-03-15
PCT/IB2020/000177 WO2020188352A1 (en) 2019-03-15 2020-03-13 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Publications (1)

Publication Number Publication Date
CN113784717A true CN113784717A (zh) 2021-12-10

Family

ID=71092560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080033296.0A Pending CN113784717A (zh) 2019-03-15 2020-03-13 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药

Country Status (9)

Country Link
US (2) US11576915B2 (https=)
EP (1) EP3938043A1 (https=)
JP (1) JP2022525202A (https=)
KR (1) KR20210139293A (https=)
CN (1) CN113784717A (https=)
AU (1) AU2020244278A1 (https=)
CA (1) CA3133589A1 (https=)
MX (1) MX2021011224A (https=)
WO (1) WO2020188352A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US11607413B2 (en) * 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009561A1 (en) * 2007-07-11 2009-01-15 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2015035113A1 (en) * 2013-09-06 2015-03-12 Karos Pharmaceuticals, Inc. Spirocyclic compounds as tryptophan hydroxylase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009561A1 (en) * 2007-07-11 2009-01-15 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2015035113A1 (en) * 2013-09-06 2015-03-12 Karos Pharmaceuticals, Inc. Spirocyclic compounds as tryptophan hydroxylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT J. AIELLO ET AL: "Tryptophan hydroxylase 1(TPH1) inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension", pages 1 *

Also Published As

Publication number Publication date
US11576915B2 (en) 2023-02-14
US20200289510A1 (en) 2020-09-17
AU2020244278A1 (en) 2021-09-30
JP2022525202A (ja) 2022-05-11
KR20210139293A (ko) 2021-11-22
EP3938043A1 (en) 2022-01-19
US20240024316A1 (en) 2024-01-25
WO2020188352A1 (en) 2020-09-24
CA3133589A1 (en) 2020-09-24
MX2021011224A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
CN113242736A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
US7834056B2 (en) Pharmaceutical composition for gout
EA030145B1 (ru) Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
US8748488B2 (en) Methods and compositions for administration of oxybutynin
TWI777059B (zh) 肌肉減少症之預防劑及治療劑
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
HK40058221A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
JP6976577B2 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
EP0310259B1 (en) Eperisone as a hypotensive agent
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
JP6875747B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
EP4065129A1 (fr) Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
WO2005000293A1 (ja) 脳血管障害に伴う過活動膀胱治療剤
CN107970248A (zh) 异甘草酸在制备治疗高血压药物中的用途
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065546

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211210